A Pilot Study to Assess the Safety Profile of resB®

NCT ID: NCT05173168

Last Updated: 2022-04-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-11-23
• Study Completion Date: 2022-01-20

Brief Summary

The study investigates the safety and tolerability of 4-week, twice daily supplementation of resB® Lung Support in asthma patients and healthy participants.

Detailed Description

resB® Lung Support is a probiotic dietary supplement that contains 3 probiotic strains and 3 herbal extracts: turmeric, holy basil, and vasaka. The proprietary herbal and probiotic blend is formulated to support proper lung structure and function. The study investigates the safety and tolerability of twice-daily supplementation of resB® Lung Support in asthma patients and healthy participants for 4 weeks.

Conditions

Healthy; Asthma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Probiotic Dietary Supplement

resB® Lung Support - 1 capsule 2x daily for 4 weeks

Group Type: EXPERIMENTAL

Probiotic Dietary Supplement

Intervention Type: DIETARY_SUPPLEMENT

Probiotic dietary supplement containing 3 probiotic strains and 3 herbal extracts

Interventions

Probiotic Dietary Supplement

Probiotic dietary supplement containing 3 probiotic strains and 3 herbal extracts

Intervention Type: DIETARY_SUPPLEMENT

Other Intervention Names

resB® Lung Support

Eligibility Criteria

Inclusion Criteria

1. Be able to give written informed consent.

2. Be between 18 - 65 years.

3. Has a stable body weight (≤5 % change) over the past 3-months.

4. Is in general good health, as determined by the investigator.

5. Avoid consuming probiotics within 12 weeks prior to baseline visit, until the end of the trial.

6. Has asthma and on stable medication for at least 3 months (confirmed by prescribed medication) AND/OR be general good health at the discretion of the investigator.

7. Maintain current level of physical activity.

8. Willing to consume the investigational product daily for the duration of the trial.

Exclusion Criteria

1. Are less than 18 or greater than 65.

2. Participants who are pregnant, breastfeeding, or wish to become pregnant during the trial.

3. Participants currently of child-bearing potential, but not using an effective method of contraception, as outlined below:

1. Complete abstinence from intercourse two weeks prior to administration of the investigational product, throughout the clinical trial, until the completion of follow-up procedures or for two weeks following discontinuation of the investigational product in cases where participant discontinues the trial prematurely. (Participants utilising this method must agree to use an alternate method of contraception if they should become sexually active and will be queried on whether they have been abstinent in the preceding 2 weeks when they present to the clinic for the Final Visit).

2. Has a male sexual partner who is surgically sterilised prior to the Screening Visit and is the only male sexual partner for that participant.

3. Sexual partner(s) is/are exclusively female.

4. Use of acceptable method of contraception, such as a spermicide, mechanical barrier (e.g. male condom, female diaphragm) or contraceptive pill. The participant must be using this method for at least 1 week following the end of the trial.

5. Use of any non-hormonal intrauterine device (IUD) or contraceptive implant with published data showing that the highest expected failure rate is less than 1 % per year. The participant must have the device inserted at least 2 weeks prior to the first Screening Visit, throughout the trial, and 2 weeks following the end of the trial.

4. Are hypersensitive or known allergy to any of the components of the investigational product.

5. Has taken antibiotics within the previous 12 weeks.

6. Has taken probiotics within the previous 12 weeks.

7. Has taken oral steroids (>10 mg/day) for more than 3 days in the previous 12 weeks.

8. Taking any immunosuppressive medications which in the opinion of the investigator are likely to have an impact on the outcomes of the trial.

9. Has made any major dietary changes in the 30 days prior to enrolment.

10. Change in medications or supplements in the 30 days prior to enrolment.

11. Have an acute or chronic illness (e.g., heart disease, inflammatory bowel disease, cancer, HIV) that, in the Investigators judgment, precludes involvement in the study

12. No more than 2 hospital admissions in the previous 6 months asthma population)

13. Presence of the following in a urine drug screen- Amphetamine/Ecstasy; Benzodiazepines; 6-Monoacetyl Morphine (6-MAM); Cocaine; Creatinine; EDDP; Opiates; Tricyclic Antidepressants; pH Detect

14. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.

15. Participants may not be receiving treatment involving experimental drugs. If the participant has been in a recent experimental trial, these must have been completed not less than 3-months prior to this trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Atlantia Food Clinical Trials

INDUSTRY

Sponsor Role: collaborator

ResBiotic Nutrition, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Timothy Dinan

Role: PRINCIPAL_INVESTIGATOR

Atlantia Food Clinical Trials

Locations

Atlantia Clinical Trials, 1st Floor, Block C, Heron House, Retail Park

Blackpool, Cork, Ireland

Countries

Ireland

References

Wenger NM, Qiao L, Nicola T, Nizami Z, Martin I, Halloran BA, Tanaka K, Evans M, Xu X, Dinan TG, Kakilla C, DunnGalvin G, Ambalavanan N, Willis KA, Gaggar A, Lal CV. Clinical trial of a probiotic and herbal supplement for lung health. Front Nutr. 2023 Jun 13;10:1168582. doi: 10.3389/fnut.2023.1168582. eCollection 2023.

Reference Type: DERIVED

PMID: 37384109 (View on PubMed)

Other Identifiers

RESB101

Identifier Type: -

Identifier Source: org_study_id